Real-World Analysis of Survival and Treatment Efficacy in Stage IIIA-N2 Non-Small Cell Lung Cancer
This study highlights the complexity and diversity of Stage IIIA-N2 NSCLC, with no single superior treatment strategy identified. The findings underscore the necessity for personalised treatment approaches and multidisciplinary decision-making. Future research should focus on integrating newer therapeutic modalities and conducting multi-centre trials to refine treatment strategies. Collaboration and ongoing data collection are crucial for improving personalised treatment plans and survival outcomes for Stage IIIA-N2 NSCLC patients.
Authors
- Daniel Smith (ORCID: https://orcid.org/0000-0002-6330-3936)
- Andrea Billè (ORCID: https://orcid.org/0000-0003-4709-4174)
- Mieke Van Hemelrijck (ORCID: https://orcid.org/0000-0002-7317-0858)
- Michael Skwarski
- Eleni Karapanagiotou
- James Spicer (ORCID: https://orcid.org/0000-0003-3732-8491)
- Karen Harrison‐Phipps
- John Pilling
- Akshay Jatin Patel (ORCID: https://orcid.org/0000-0001-9170-8618)
- Alexandros Georgiou (ORCID: https://orcid.org/0000-0001-7500-9251)
- Eleni Josephides
- Annie-Rose Henry (ORCID: https://orcid.org/0009-0005-8037-6546)
- Roberta Dunn (ORCID: https://orcid.org/0009-0003-7253-9128)
- Sharmistha Ghosh
- Shahreen Ahmad
Institutions
- King's College London (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- London Cancer (GB)
Publication Details
- Journal
- Cancers
- Published
- 2024-09-02
- DOI
- https://doi.org/10.3390/cancers16173058
- Citations
- 2
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.84